We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nanobiochip Diagnoses Heart Attacks

By LabMedica International staff writers
Posted on 12 May 2010
A diagnostic tool developed by scientists to detect heart attacks using a person's saliva is being tested in human trials.

A microchip sensor, the nanobiochip, processes the saliva and yields on-the-spot results. More...
To obtain a saliva sample for the device, health care providers swab a patient's gums with a cotton-tipped stick. The saliva is transferred to the disposable diagnostic microchip. The microchip is then inserted into an analyzer and within a few minutes the saliva sample is checked and results delivered.

Nanobiochips deliver all the capabilities of a traditional laboratory but do not require expensive instrumentation to get results. Manufactured with techniques pioneered by the microelectronics industry, they are able to analyze large amounts of biomarker data at significantly lower cost than traditional tests.

The nanobiochip was developed at Rice University (Houston, TX, USA). It is being tested in human trials at the Michael E. DeBakey VA Medical Center (MEDVAMC; Houston, TX, USA) in collaboration with Baylor College of Medicine (BCM; Houston, TX, USA). Over the next two years, samples from approximately 500 patients who come to the MEDVAMC emergency room with chest pain or heart attack-related symptoms will be collected for the trial.

"We find salivary tests, when combined with electrocardiograms (ECGs), can provide more accurate information than the ECG alone for patients with chest pain," John T. McDevitt, professor of chemistry and bioengineering at Rice said. "Saliva-based tests have the potential to quickly diagnose heart-attack victims as well as to find false alarms."

Chest pain brings about 5 million patients to U.S. emergency rooms each year, but 80 % of those patients are not suffering heart attacks. Blood test results can take anywhere from 90 minutes to three hours, and in many cases it may be 12 to 24 hours before patients know whether or not they had a heart attack.

Prof. McDevitt said that the new test could save lives, time, and money by allowing doctors to identify those suffering from a heart attack before administering a battery of costly tests.

Related Links:

Rice University
Michael E. DeBakey VA Medical Center
Baylor College of Medicine



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.